Vigencell, a company specializing in immune cell treatments’ research and development, said it plans to go public in the Kosdaq stock market next week.  Ahead of its IPO, the company presented its major pipelines, competitiveness, visions, and strategies in a news conference on Thursday.

Vigencell aims to raise about 99.4 billion won ($87 million) by issuing 1.88 million shares with its offering price set at 42,800 won-52,700 won.

It will finalize the offering price next Wednesday and receives subscriptions in the following two days. Based on its offering price, the market cap is between 403.7 billion and 497.2 billion won.

“We will maximize the company's competitiveness by strengthening and expanding the pipeline with strategic investment on R&D and footholds in the propriety platform technology,” CEO Kim Tai-gyu said. “With the IPO, we will speed up the development of new and innovative drugs. We will develop into the world’s best immune cell therapy producer by producing output with future clinical trials and technology transfer.”

Vigencell was established in 2013. It is producing immune-oncology and immunosuppressants for cancer, immune disorders, and other diseases. In 2017, Boryung Pharma became its largest shareholder as a strategic partner.

The company plans to speed up clinical trials, commercialization and expand its share in the global market. Its strengths include excellent business expandability based on platform technology, construction of a mutually complementary pipeline that provides for personalized and generally used treatment, anticipation on early commercialization in the major pipeline, R&D ability of excellent research team and international scientific advisory committee, and strategic synergy with the partner company Boryung Pharma.

It focuses on the early commercialization of NK-T cell lymphoma treatment which has a technological advantage in its core pipeline. With its basis on platform technology, it has high business expandability anticipated. Aided with its immune-oncology and immune-depressant products, it plans to march towards the global market.

“Lastly, by going public, the company will speed up its clinical trials, R&D and construct cGMP and expand investments,” Kim said.